$5.63
0.050.90%
At close: -
$5.63
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Enanta Pharma Analyst Ratings and Price Targets | NASDAQ:ENTA | Benzinga
Enanta Pharmaceuticals Inc has a consensus price target of $35.55 based on the ratings of 11 analysts. The high is $87 issued by Piper Sandler on February 8, 2023. The low is $10 issued by JP Morgan on August 6, 2024. The 3 most-recent analyst ratings were released by JMP Securities, HC Wainwright & Co., and HC Wainwright & Co. on February 11, 2025, February 11, 2025, and December 24, 2024, respectively. With an average price target of $19 between JMP Securities, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 237.48% upside for Enanta Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
HC Wainwright & Co.
Baird
JP Morgan
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Enanta Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/11/2025 | Buy Now | 273% | JMP Securities | Roy Buchanan34% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/11/2025 | Buy Now | 219.72% | HC Wainwright & Co. | Ed Arce58% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 12/24/2024 | Buy Now | 219.72% | HC Wainwright & Co. | Ed Arce58% | $27 → $18 | Maintains | Buy | Get Alert |
| 11/26/2024 | Buy Now | 255.24% | Baird | Brian Skorney58% | $26 → $20 | Maintains | Outperform | Get Alert |
| 11/26/2024 | Buy Now | 273% | JMP Securities | Roy Buchanan34% | $22 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 10/10/2024 | Buy Now | 379.57% | HC Wainwright & Co. | Ed Arce58% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | 290.76% | JMP Securities | Roy Buchanan34% | $22 → $22 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/27/2024 | Buy Now | 290.76% | JMP Securities | Roy Buchanan34% | $22 → $22 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/06/2024 | Buy Now | 77.62% | JP Morgan | Eric Joseph43% | $11 → $10 | Maintains | Underweight | Get Alert |
| 08/06/2024 | Buy Now | 379.57% | HC Wainwright & Co. | Ed Arce58% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 379.57% | HC Wainwright & Co. | Ed Arce58% | $28 → $27 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 290.76% | JMP Securities | Roy Buchanan34% | $23 → $22 | Maintains | Market Outperform | Get Alert |
| 02/08/2024 | Buy Now | 95.38% | JP Morgan | Eric Joseph43% | $12 → $11 | Maintains | Underweight | Get Alert |
| 11/22/2023 | Buy Now | 273% | Oppenheimer | Jay Olson61% | $25 → $21 | Maintains | Perform | Get Alert |
| 11/21/2023 | Buy Now | 397.34% | HC Wainwright & Co. | Ed Arce58% | $30 → $28 | Maintains | Buy | Get Alert |
| 11/21/2023 | Buy Now | 308.53% | JMP Securities | Roy Buchanan34% | $42 → $23 | Maintains | Outperform | Get Alert |
| 10/23/2023 | Buy Now | 432.86% | HC Wainwright & Co. | Ed Arce58% | $48 → $30 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 166.43% | RBC Capital | Brian Abrahams48% | $25 → $15 | Maintains | Sector Perform | Get Alert |
| 09/19/2023 | Buy Now | 752.58% | HC Wainwright & Co. | Ed Arce58% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 344.05% | Oppenheimer | Jay Olson61% | $30 → $25 | Maintains | Perform | Get Alert |
| 08/08/2023 | Buy Now | 752.58% | HC Wainwright & Co. | Ed Arce58% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 344.05% | RBC Capital | Brian Abrahams48% | → $25 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/08/2023 | Buy Now | 646% | JMP Securities | Roy Buchanan34% | $65 → $42 | Maintains | Market Outperform | Get Alert |
| 08/08/2023 | Buy Now | 219.72% | Jefferies | Akash Tewari44% | $49 → $18 | Downgrade | Buy → Hold | Get Alert |
| 05/11/2023 | Buy Now | 432.86% | Oppenheimer | Jay Olson61% | $50 → $30 | Reiterates | Perform → Perform | Get Alert |
| 05/09/2023 | Buy Now | 486.15% | RBC Capital | Brian Abrahams48% | $48 → $33 | Maintains | Sector Perform | Get Alert |
| 05/09/2023 | Buy Now | 752.58% | HC Wainwright & Co. | Ed Arce58% | $68 → $48 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 1054.53% | JMP Securities | Roy Buchanan34% | $82 → $65 | Maintains | Outperform | Get Alert |
| 03/22/2023 | Buy Now | 859.15% | RBC Capital | Brian Abrahams48% | → $54 | Reiterates | → Sector Perform | Get Alert |
| 02/09/2023 | Buy Now | 770.34% | SVB Leerink | Roanna Ruiz34% | → $49 | Reiterates | → Market Perform | Get Alert |
| 02/08/2023 | Buy Now | 1445.29% | Piper Sandler | Yasmeen Rahimi58% | → $87 | Maintains | Overweight | Get Alert |
| 02/08/2023 | Buy Now | 965.72% | JP Morgan | Eric Joseph43% | $74 → $60 | Maintains | Neutral | Get Alert |
| 01/27/2023 | Buy Now | 770.34% | SVB Leerink | Roanna Ruiz34% | $50 → $49 | Maintains | Market Perform | Get Alert |
| 12/09/2022 | Buy Now | 894.67% | HC Wainwright & Co. | Ed Arce58% | → $56 | Initiates | → Buy | Get Alert |
| 11/22/2022 | Buy Now | 859.15% | RBC Capital | Brian Abrahams48% | $65 → $54 | Maintains | Sector Perform | Get Alert |
| 08/10/2022 | Buy Now | 947.96% | Oppenheimer | Jay Olson61% | $53 → $59 | Maintains | Perform | Get Alert |
| 08/09/2022 | Buy Now | 2333.39% | JMP Securities | Roy Buchanan34% | $103 → $137 | Maintains | Market Outperform | Get Alert |
| 08/09/2022 | Buy Now | 1072.29% | RBC Capital | Brian Abrahams48% | $67 → $66 | Maintains | Sector Perform | Get Alert |
| 08/01/2022 | Buy Now | 841.39% | Oppenheimer | Jay Olson61% | $45 → $53 | Maintains | Perform | Get Alert |
| 08/01/2022 | Buy Now | 788.1% | SVB Leerink | Roanna Ruiz34% | $44 → $50 | Maintains | Market Perform | Get Alert |
| 07/06/2022 | Buy Now | 1001.24% | Evercore ISI Group | Liisa Bayko70% | → $62 | Upgrade | In-Line → Outperform | Get Alert |
| 07/01/2022 | Buy Now | 1090.05% | RBC Capital | Brian Abrahams48% | $64 → $67 | Maintains | Sector Perform | Get Alert |
| 06/01/2022 | Buy Now | 592.72% | Evercore ISI Group | Liisa Bayko70% | → $39 | Upgrade | Underperform → In-Line | Get Alert |
| 05/20/2022 | Buy Now | 699.29% | Oppenheimer | Jay Olson61% | $70 → $45 | Maintains | Outperform | Get Alert |
| 05/19/2022 | Buy Now | 1498.58% | Baird | Brian Skorney58% | $130 → $90 | Maintains | Outperform | Get Alert |
| 05/19/2022 | Buy Now | 1729.48% | JMP Securities | Roy Buchanan34% | $114 → $103 | Maintains | Market Outperform | Get Alert |
| 05/19/2022 | Buy Now | 681.53% | SVB Leerink | Roanna Ruiz34% | $58 → $44 | Maintains | Market Perform | Get Alert |
| 05/12/2022 | Buy Now | 1143.34% | Roth Capital | Zegbeh Jallah65% | $101 → $70 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 1924.87% | JMP Securities | Roy Buchanan34% | $116 → $114 | Maintains | Market Outperform | Get Alert |
| 05/10/2022 | Buy Now | 930.2% | SVB Leerink | Roanna Ruiz34% | $68 → $58 | Maintains | Market Perform | Get Alert |
| 05/10/2022 | Buy Now | 1036.77% | RBC Capital | Brian Abrahams48% | $72 → $64 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Enanta Pharma (ENTA) stock?
The latest price target for Enanta Pharma (NASDAQ:ENTA) was reported by JMP Securities on February 11, 2025. The analyst firm set a price target for $21.00 expecting ENTA to rise to within 12 months (a possible 273.00% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enanta Pharma (ENTA)?
The latest analyst rating for Enanta Pharma (NASDAQ:ENTA) was provided by JMP Securities, and Enanta Pharma reiterated their market outperform rating.
When was the last upgrade for Enanta Pharma (ENTA)?
The last upgrade for Enanta Pharmaceuticals Inc happened on July 6, 2022 when Evercore ISI Group raised their price target to $62. Evercore ISI Group previously had an in-line for Enanta Pharmaceuticals Inc.
When was the last downgrade for Enanta Pharma (ENTA)?
The last downgrade for Enanta Pharmaceuticals Inc happened on August 8, 2023 when Jefferies changed their price target from $49 to $18 for Enanta Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Enanta Pharma (ENTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.
Is the Analyst Rating Enanta Pharma (ENTA) correct?
While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a reiterated with a price target of $21.00 to $21.00. The current price Enanta Pharma (ENTA) is trading at is $5.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
